Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for VRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 20.25B
March 31, 2026 19.36B
December 31, 2025 18.67B
September 30, 2025 17.32B
June 30, 2025 17.18B
March 31, 2025 16.50B
December 31, 2024 16.41B
September 30, 2024 15.63B
June 30, 2024 14.77B
March 31, 2024 18.55B
December 31, 2023 17.58B
September 30, 2023 16.51B
June 30, 2023 15.47B
March 31, 2023 14.43B
December 31, 2022 13.91B
September 30, 2022 13.03B
June 30, 2022 11.93B
March 31, 2022 10.91B
December 31, 2021 10.10B
September 30, 2021 9.531B
June 30, 2021 9.196B
March 31, 2021 8.980B
December 31, 2020 8.687B
September 30, 2020 8.133B
June 30, 2020 7.519B
Date Value
March 31, 2020 6.462B
December 31, 2019 6.085B
September 30, 2019 5.253B
June 30, 2019 5.070B
March 31, 2019 4.723B
December 31, 2018 4.435B
September 30, 2018 2.906B
June 30, 2018 2.686B
March 31, 2018 2.401B
December 31, 2017 2.029B
September 30, 2017 1.791B
June 30, 2017 1.671B
March 31, 2017 1.500B
December 31, 2016 1.157B
September 30, 2016 1.022B
June 30, 2016 981.35M
March 31, 2016 957.08M
December 31, 2015 939.97M
September 30, 2015 922.15M
June 30, 2015 894.96M
March 31, 2015 976.46M
December 31, 2014 1.075B
September 30, 2014 1.156B
June 30, 2014 1.172B
March 31, 2014 1.231B

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 11.83B
Alnylam Pharmaceuticals, Inc. 1.354B
Regeneron Pharmaceuticals, Inc. 31.71B
Sionna Therapeutics, Inc. 265.78M
Biogen, Inc. 18.85B

Shareholders Equity (Quarterly) Related Metrics